These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6215922)

  • 21. Effects of N-hydroxy-N'-aminoguanidine isoquinoline in combination with other inhibitors of ribonucleotide reductase on L1210 cells.
    Weckbecker G; Weckbecker A; Lien EJ; Cory JG
    J Natl Cancer Inst; 1988 Jun; 80(7):491-6. PubMed ID: 2452889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of 5-fluorouracil on 5-fluorodeoxyuridine 5'-monophosphate and 2-deoxyuridine 5'-monophosphate pools, and DNA synthesis in solid mouse L1210 and rat Walker 256 tumors.
    Klubes P; Connelly K; Cerna I; Mandel HG
    Cancer Res; 1978 Aug; 38(8):2325-31. PubMed ID: 667828
    [No Abstract]   [Full Text] [Related]  

  • 23. Mouse leukemia L1210 cells selected for resistance to the ribonucleotide reductase inhibitor, 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone show altered response to DNA damaging agents.
    Crenshaw TR; Cory JG
    Int J Oncol; 1999 Sep; 15(3):487-90. PubMed ID: 10427129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
    Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
    Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential selectivity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in cultured human B lymphocytes and mouse L1210 leukemia.
    Au JL; Rustum YM; Minowada J; Srivastava BI
    Biochem Pharmacol; 1983 Feb; 32(3):541-6. PubMed ID: 6221728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells.
    Keyomarsi K; Moran RG
    Cancer Res; 1986 Oct; 46(10):5229-35. PubMed ID: 2944577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
    Sato A; Carter GL; Bacon PE; Cory JG
    Adv Enzyme Regul; 1983; 21():259-70. PubMed ID: 6400064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of combination chemotherapy of MCNU with various anti-cancer agents].
    Machida S; Ito Y; Hoshino A
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):298-302. PubMed ID: 3918506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolation of fluoropyrimidine-resistant murine leukemic cell lines by one-step mutation and selection.
    Mulkins MA; Heidelberger C
    Cancer Res; 1982 Mar; 42(3):956-64. PubMed ID: 6460554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents.
    Gale GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
    Cancer Treat Rep; 1977; 61(3):445-50. PubMed ID: 872142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells.
    Chitambar CR; Narasimhan J; Guy J; Sem DS; O'Brien WJ
    Cancer Res; 1991 Nov; 51(22):6199-201. PubMed ID: 1933878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
    Sato A; Carter GL; Bacon PE; Cory JG
    Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N'-aminoguanidine derivatives.
    Cory JG; Carter GL; Bacon PE; T'ang A; Lien EJ
    Biochem Pharmacol; 1985 Aug; 34(15):2645-50. PubMed ID: 3893440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents.
    Elford HL; Van't Riet B; Wampler GL; Lin AL; Elford RM
    Adv Enzyme Regul; 1980; 19():151-68. PubMed ID: 6175187
    [No Abstract]   [Full Text] [Related]  

  • 35. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
    van Laar JA; Durrani FA; Rustum YM
    Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
    Klubes P; Cerna I
    Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative physiologic dispositions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia.
    Chadwick M; Chang C
    Cancer Treat Rep; 1976 Jul; 60(7):845-55. PubMed ID: 137772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of thymidylate synthetase activity in development of methotrexate cytotoxicity.
    Moran RG; Mulkins M; Heidelberger C
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5924-8. PubMed ID: 160558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Experimental combination chemotherapy of YNK01, a novel analog of cytarabine, with other antitumor agents].
    Uchida T; Nagahata T; Arakawa M; Ekimoto H; Takahashi K
    Gan To Kagaku Ryoho; 1990 Jul; 17(7):1351-6. PubMed ID: 2114829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorinated pyrimidines. XXIX. Syntheses of 2',3'-dehydro-5-fluoro-2'-deoxyuridine and 2',3'-dideoxy-5-fluorouridine.
    Khwaja TA; Heidelberger C
    J Med Chem; 1967 Nov; 10(6):1066-70. PubMed ID: 4293494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.